 Connection
Vanessa Fabrizio to Adult
This is a "connection" page, showing publications Vanessa Fabrizio has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.113 |
|
|
|
-
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):1961-1968.
Score: 0.038
-
Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ. Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
Score: 0.012
-
Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, Wang HW, Kovach AE, Yuan CM, Delgado Colon D, Vasseur L, Bataller A, John S, Utley Lyons K, Friedes B, Alonso-Saladrigues A, Abdel-Azim H, Balducci E, Aljudi AA, Balsat M, Biery DN, Chamdin A, Chang BH, Cuevo RS, De Moerloose B, Dickens DS, Duffner U, Duployez N, El Chaer F, Elliott MA, Escherich G, Fernandes S, Fitzjohn MR, Gahvari Z, Grupp SA, He RR, Harrison C, Hergott CB, Hsieh EM, Kim AS, Kuo DJ, Larson DP, Lee BJ, Leguay T, Lindsley RC, Mangaonkar AA, Mezger K, Pacenta HL, Pan J, Provost M, Puri L, Raikar SS, Martinez A, Bristol I, Murphy K, Reiman L, Redell M, Reed K, Roth-Guepin G, Rubinstein J, Savasan S, Schafernak K, Stevens A, Talleur A, Torres Carapia N, Vargaftig J, Vatsayan A, Wölfl M, Zhao L, Rives S, Fabrizio VA, Sasaki K, Aldoss I, Boissel N, Rheingold SR, Davis KL, Ghorashian S, Jacoby E, Popov A, Lamble AJ, Shah NN. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025 Jul 24; 146(4):437-455.
Score: 0.012
-
Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff JE, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras N, Baumeister SHC, Cooper SL, Hermiston M, Satwani P, Qayed M, Raikar SS, MacMillan M, Hall E, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy P, Schwartz MS, Ladha A, Yaghmour G, Kumaran MV, Bachanova V, Tracy S, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Shah BD, Muffly L, Faramand R. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025 Jun 10; 9(11):2763-2772.
Score: 0.012
-
Talleur AC, Fabrizio VA, Aplenc R, Grupp SA, Mackall C, Majzner R, Nguyen R, Rouce R, Moskop A, McNerney KO. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther. 2024 06; 30(6):565-579.
Score: 0.011
-
Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski MC, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023 02 28; 7(4):541-548.
Score: 0.010
-
Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 11 25; 138(21):2138-2142.
Score: 0.009
-
Sabnis HS, Shulman DS, Mizukawa B, Bouvier N, Zehir A, Fangusaro J, Fabrizio VA, Whitlow C, Winchester M, Agresta L, Turpin B, Wechsler DS, DuBois SG, Glade-Bender J, Castellino SM, Shukla N. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021 12 01; 39(34):3822-3828.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|